Biological E partners with China’s Recbio to produce REC603 a 9-valent HPV vaccine in India The collaboration aims to expand ...

Biological E Ltd. has partnered with Jiangsu Recbio Technology to commercialize the latter's HPV9 vaccine, REC603, in India.

Low screening coverage, late diagnoses, high HIV prevalence, and limited access to treatment and vaccines are driving cervical cancer cases and deaths in South Africa. The country has a cervical ...

Jiangsu Recbio Technology and Biological E. Limited are partnering for HPV9 vaccine. Recbio will transfer technology to ...

HYDERABAD: Jiangsu Recbio Technology Co. Ltd, a leading Chinese biopharmaceutical firm, has entered into a licensing and ...

According to the agreement, BE will receive the exclusive right to commercialise the vaccine in India and participate in ...

The implementation of these three key pillars — vaccination, screening, and treatment — are critical in eliminating cervical ...

Your premium access has ended, but the best of Nation.Africa is still within reach. Renew now to unlock exclusive stories and ...

A growing number of oncologists across India have expressed concern over Human Papillomavirus (HPV) becoming a major ...

Unlike other cancers that develop over decades, HPV-related cancers in young people often progress rapidly and silently.

New members of the ACIP began their tenure by shifting the posture of the 60-year-old panel from support for vaccine ...

Nagpur: \"HPV vaccines are not only for girls. boys from 9 to 26 years of age should also take them. HPV isn't just about ...